Marinus Pharmaceuticals, Inc. (MRNS) News
Filter MRNS News Items
MRNS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MRNS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest MRNS News From Around the Web
Below are the latest news stories about MARINUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MRNS as an investment opportunity.
Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should KnowMarinus Pharmaceuticals (MRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Marinus Pharmaceuticals to be acquired by Immedica for 55c per shareImmedica Pharma and Marinus Pharmaceuticals (MRNS) announced that they have entered into an agreement and plan of merger under which Immedica has agreed to acquire Marinus, by means of a tender offer and subsequent merger. The transaction adds global rights to Zealmy, a commercial-stage rare neurology medicine approved by FDA, the European Commission, the UK Medicines and Healthcare products Regulatory Agency and the National Medicines Product Administration in China with potential for further a |
Immedica to buy Marinus Pharmaceuticals for $151mThe deal is anticipated to expand Immedica’s rare disease portfolio by adding ZTALMY oral suspension, CV. |
Immedica to Acquire Marinus Pharmaceuticals in $151 Million Deal; Shares Surge 43%The transaction expands Immedica's presence in North America and enhances its rare disease portfolio. |
Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40%Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) shares are trading higher on Monday after the company entered into a merger agreement to be acquired by Immedica Pharma AB, implying an enterprise value of approximately $151 million. As per the deal, Immedica will launch a tender offer through a wholly owned subsidiary to acquire all outstanding shares of Marinus common stock at $0.55 per share in cash. This represents a 48% premium over Marinus’ December 27 closing price and a 97% premium over the 30 |
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.STOCKHOLM & RADNOR, Pa., December 30, 2024--Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, today announced that they have entered into an agreement and plan of merger under which Immedica has agreed to acquire Marinus, by means of a tender offer and subsequent merger. |
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest ResultsIt's been a sad week for Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ), who've watched their investment drop 14% to... |
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue EstimatesMarinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 4.55% and 4.59%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Marinus Pharmaceuticals: Q3 Earnings SnapshotRADNOR, Pa. AP) — Marinus Pharmaceuticals Inc. MRNS) on Tuesday reported a loss of $24.2 million in its third quarter. |
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial ResultsRADNOR, Pa., November 12, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2024. |